nach oben

Breast Cancer Research

Erschienen in:

01.08.2004 | Commentary

Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group

verfasst von: Emiel JT Rutgers, Philip Meijnen, Hervé Bonnefoi

Erschienen in: Breast Cancer Research | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

The present clinical trial update consists of a review of two of eight current studies (the 10981-22023 AMAROS trial and the 10994 p53 trial) of the European Organization for Research and Treatment of Cancer Breast Cancer Group, as well as a preview of the MIND-ACT trial. The AMAROS trial is designed to prove equivalent local/regional control for patients with proven axillary lymph node metastasis by sentinel node biopsy if treated with axillary radiotherapy instead of axillary lymph node dissection, with reduced morbidity. The p53 trial started to assess the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane regimen versus a nontaxane regimen.

Nur mit Berechtigung zugänglich

Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, Glass EC, Turner RR: Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000, 18: 2553-2559.PubMed

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G, De Cicco C, De Lucia F, Gennari R: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003, 349: 546-553. 10.1056/NEJMoa012782.CrossRefPubMed

Rutgers EJ: Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?. Eur J Cancer. 2004, 40: 182-186. 10.1016/j.ejca.2003.09.025.CrossRefPubMed

Bourez RL, Rutgers EJ: The European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Group: quality control of surgical trials. Surg Oncol Clin N Am. 2001, 10: 807-819. ixPubMed

Bass SS, Cox CE, Reintgen DS: Learning curves and certification for breast cancer lymphatic mapping. Surg Oncol Clin N Am. 1999, 8: 497-509.PubMed

Giuliano AE, Kirgan DM, Guenther JM, Morton DL: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994, 220: 391-398.CrossRefPubMedPubMedCentral

Orr RK, Hoehn JL, Col NF: The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999, 134: 764-767. 10.1001/archsurg.134.7.764.CrossRefPubMed

Bentzen SM, Bernier J, Davis JB, Horiot JC, Garavaglia G, Chavaudra J, Johansson KA, Bolla M: Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. Eur J Cancer. 2000, 36: 615-620. 10.1016/S0959-8049(99)00336-6.CrossRefPubMed

Horiot JC, Johansson KA, Gonzalez DG, van der Schueren E, van den Bogaert W, Notter G: Quality assurance control in the EORTC cooperative group of radiotherapy. 1. Assessment of radiotherapy staff and equipment. European Organization for Research and Treatment of Cancer. Radiother Oncol. 1986, 6: 275-284.CrossRefPubMed

10.

Johansson KA, Horiot C, Van Dam J, Lepinoy D, Sentenac I, Sernbo G: Quality assurance control in the EORTC cooperative group of radiotherapy. 2. Dosimetric intercomparison. Radiother Oncol. 1986, 7: 269-279.CrossRefPubMed

11.

Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G: Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiother Oncol. 2003, 68: 233-240. 10.1016/S0167-8140(03)00194-4.CrossRefPubMed

12.

Weigelt B, Verduijn P, Bosma AJ, Rutgers EJ, Peterse HL, Van't Veer LJ: Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br J Cancer. 2004, 90: 1531-1537. 10.1038/sj.bjc.6601659.CrossRefPubMedPubMedCentral

13.

Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992, 11: 121-139. 10.1007/BF00048059.CrossRefPubMed

14.

Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM: Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res. 1998, 4: 1047-1054.PubMed

15.

Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T: p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA. 1997, 94: 9679-9683. 10.1073/pnas.94.18.9679.CrossRefPubMedPubMedCentral

16.

Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993, 74: 957-967. 10.1016/0092-8674(93)90719-7.CrossRefPubMed

17.

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science. 1994, 266: 807-810.CrossRefPubMed

18.

O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57: 4285-4300.PubMed

19.

Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med. 1996, 2: 72-79. 10.1038/nm0196-72.CrossRefPubMed

20.

Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995, 1: 506-526.PubMedPubMedCentral

21.

Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996, 2: 811-814. 10.1038/nm0796-811.CrossRefPubMed

22.

Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88: 173-182. 10.1093/jnci/88.3.173.CrossRefPubMed

23.

Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA. 1995, 92: 3963-3967.CrossRefPubMedPubMedCentral

Titel: Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
verfasst von: Emiel JT Rutgers
Philip Meijnen
Hervé Bonnefoi
Publikationsdatum: 01.08.2004
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 4/2004
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr906

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer

Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: a case control study

Expression of hypoxia-inducible factor-1α and cell cycle proteins in invasive breast cancer are estrogen receptor related

First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases

Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes

Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case–control study of African Americans and whites

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie